The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hepatocellular Carcinoma Drugs-Global Market Insights and Sales Trends 2024
Synopsis
HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
The global Hepatocellular Carcinoma Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatocellular Carcinoma Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Cancer Rehabilitation Centers,, are propelling Hepatocellular Carcinoma Drugs market. Brachytherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatocellular Carcinoma Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hepatocellular Carcinoma Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hepatocellular Carcinoma Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatocellular Carcinoma Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hepatocellular Carcinoma Drugs covered in this report include Bayer, Eli Lilly, Johnson and Johnson, Pfizer, Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead and GlaxoSmithKline, etc.
The global Hepatocellular Carcinoma Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Eli Lilly
Johnson and Johnson
Pfizer
Bristol-Myers Squibb
Celgene
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Novartis
Global Hepatocellular Carcinoma Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hepatocellular Carcinoma Drugs market, Segment by Type:
Brachytherapy
Chemotherapy
Local Ablation Therapy
Global Hepatocellular Carcinoma Drugs market, by Application
Hospitals
Clinics
Cancer Rehabilitation Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatocellular Carcinoma Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
The global Hepatocellular Carcinoma Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatocellular Carcinoma Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Cancer Rehabilitation Centers,, are propelling Hepatocellular Carcinoma Drugs market. Brachytherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatocellular Carcinoma Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hepatocellular Carcinoma Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hepatocellular Carcinoma Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatocellular Carcinoma Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hepatocellular Carcinoma Drugs covered in this report include Bayer, Eli Lilly, Johnson and Johnson, Pfizer, Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead and GlaxoSmithKline, etc.
The global Hepatocellular Carcinoma Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Eli Lilly
Johnson and Johnson
Pfizer
Bristol-Myers Squibb
Celgene
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Novartis
Global Hepatocellular Carcinoma Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hepatocellular Carcinoma Drugs market, Segment by Type:
Brachytherapy
Chemotherapy
Local Ablation Therapy
Global Hepatocellular Carcinoma Drugs market, by Application
Hospitals
Clinics
Cancer Rehabilitation Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatocellular Carcinoma Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hepatocellular Carcinoma Drugs
1.1 Hepatocellular Carcinoma Drugs Market Overview
1.1.1 Hepatocellular Carcinoma Drugs Product Scope
1.1.2 Hepatocellular Carcinoma Drugs Market Status and Outlook
1.2 Global Hepatocellular Carcinoma Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hepatocellular Carcinoma Drugs Market Size by Region (2018-2029)
1.4 Global Hepatocellular Carcinoma Drugs Historic Market Size by Region (2018-2023)
1.5 Global Hepatocellular Carcinoma Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hepatocellular Carcinoma Drugs Market Size (2018-2029)
1.6.1 North America Hepatocellular Carcinoma Drugs Market Size (2018-2029)
1.6.2 Europe Hepatocellular Carcinoma Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size (2018-2029)
1.6.4 Latin America Hepatocellular Carcinoma Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size (2018-2029)
2 Hepatocellular Carcinoma Drugs Market by Type
2.1 Introduction
2.1.1 Brachytherapy
2.1.2 Chemotherapy
2.1.3 Local Ablation Therapy
2.2 Global Hepatocellular Carcinoma Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hepatocellular Carcinoma Drugs Revenue Breakdown by Type (2018-2029)
3 Hepatocellular Carcinoma Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Cancer Rehabilitation Centers
3.2 Global Hepatocellular Carcinoma Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hepatocellular Carcinoma Drugs Revenue Breakdown by Application (2018-2029)
4 Hepatocellular Carcinoma Drugs Competition Analysis by Players
4.1 Global Hepatocellular Carcinoma Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2022)
4.3 Date of Key Players Enter into Hepatocellular Carcinoma Drugs Market
4.4 Global Top Players Hepatocellular Carcinoma Drugs Headquarters and Area Served
4.5 Key Players Hepatocellular Carcinoma Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Hepatocellular Carcinoma Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bayer
5.1.1 Bayer Profile
5.1.2 Bayer Main Business
5.1.3 Bayer Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.1.4 Bayer Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Bayer Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.2.4 Eli Lilly Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly Recent Developments
5.3 Johnson and Johnson
5.3.1 Johnson and Johnson Profile
5.3.2 Johnson and Johnson Main Business
5.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.3.4 Johnson and Johnson Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.4.4 Pfizer Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Pfizer Recent Developments
5.5 Bristol-Myers Squibb
5.5.1 Bristol-Myers Squibb Profile
5.5.2 Bristol-Myers Squibb Main Business
5.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.5.4 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Bristol-Myers Squibb Recent Developments
5.6 Celgene
5.6.1 Celgene Profile
5.6.2 Celgene Main Business
5.6.3 Celgene Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.6.4 Celgene Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Celgene Recent Developments
5.7 F. Hoffmann-la Roche
5.7.1 F. Hoffmann-la Roche Profile
5.7.2 F. Hoffmann-la Roche Main Business
5.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.7.4 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 F. Hoffmann-la Roche Recent Developments
5.8 Gilead
5.8.1 Gilead Profile
5.8.2 Gilead Main Business
5.8.3 Gilead Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.8.4 Gilead Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Gilead Recent Developments
5.9 GlaxoSmithKline
5.9.1 GlaxoSmithKline Profile
5.9.2 GlaxoSmithKline Main Business
5.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.9.4 GlaxoSmithKline Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 GlaxoSmithKline Recent Developments
5.10 Merck
5.10.1 Merck Profile
5.10.2 Merck Main Business
5.10.3 Merck Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.10.4 Merck Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Merck Recent Developments
5.11 Novartis
5.11.1 Novartis Profile
5.11.2 Novartis Main Business
5.11.3 Novartis Hepatocellular Carcinoma Drugs Products, Services and Solutions
5.11.4 Novartis Hepatocellular Carcinoma Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Novartis Recent Developments
6 North America
6.1 North America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hepatocellular Carcinoma Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hepatocellular Carcinoma Drugs Market Dynamics
11.1 Hepatocellular Carcinoma Drugs Industry Trends
11.2 Hepatocellular Carcinoma Drugs Market Drivers
11.3 Hepatocellular Carcinoma Drugs Market Challenges
11.4 Hepatocellular Carcinoma Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
